Exploration of a standard treatment for Buruli ulcer through a comprehensive analysis of all cases diagnosed in Japan

Journal of Dermatology

Volumn 42, Issue 6, 2015, Pages 588-595

  Sugawara, Mariko ^a,b   Ishii, Norihisa ^a,c   Nakanaga, Kazue ^c   Suzuki, Koichi ^c   Umebayashi, Yoshihiro ^d   Makigami, Kuniko ^e   Aihara, Michiko ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b West Yokohama Sugawara Dermatology Clinic   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Tsubasa Home Care Clinic   (Japan)

Author keywords

Buruli ulcer; clarithromycin; levofloxacin; Mycobacterium ulcerans; rifampicin; treatment

Indexed keywords

CLARITHROMYCIN; CYCLOSPORIN; LEVOFLOXACIN; RIFAMPICIN; STEROID; TOSUFLOXACIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BURULI ULCER; CHILD; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; JAPAN; LOW DRUG DOSE; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MONOTHERAPY; OUTCOME ASSESSMENT; RURAL POPULATION; SEASONAL VARIATION; SKIN DEFECT; SKIN SURGERY; TREATMENT DURATION; VERY ELDERLY; COMBINATION DRUG THERAPY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BURULI ULCER; CHILD; CHILD, PRESCHOOL; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; JAPAN; LEVOFLOXACIN; MALE; MIDDLE AGED; RIFAMPIN; YOUNG ADULT;

EID: 84930484784     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12851     Document Type: Article

References (28)

1. Nakanaga K, Yotsu RR, Hoshino Y, Suzuki K, Makino M, Ishii N,. Buruli ulcer and mycolactone-producing mycobacteria. Jpn J Infect Dis 2013; 66: 83-88.
2. Wansbrough-Jones M, Phillips R,. Buruli ulcer: emerging from obscurity. Lancet 2006; 367: 1849-1858.
3. Yotsu RR, Nakanaga K, Hoshino Y, Suzuki K, Ishii N,. Buruli ulcer and current situation in Japan: a new emerging cutaneous Mycobacterium infection. J Dermatol 2012; 39: 587-593.
4. Global Buruli Ulcer Initiative (GBUI), World Health Organization. Buruli ulcer endemic countries [internet]. 2011. Available from: http://www.who.int/buruli/en/.
5. Nakanaga K, Hoshino Y, Yotsu RR, Makino M, Ishii N,. Nineteen cases of Buruli ulcer diagnosed in Japan from 1980 to 2010. J Clin Microbiol 2011; 49: 3829-3836.
6. World Health Organization. Treatment of Mycobacteriumu ulcerans disease (Buruli Ulcer) Guidance for workers, World Health Organization Number of pages: v 66 p April 2012. Available from: www.who.int/buruli/treatment/en/.
7. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, Phillips R, et al,. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005; 49: 3182-3186.
8. O'Brien DP, Jenkin G, Buntine J, et al,. Treatment and prevention of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: guideline update. Med J Aust 2014; 200: 267-270.
9. Nienhuis WA, Stienstra Y, Thompson WA, et al,. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 2010; 375: 664-672.
10. Phillips RO, Sarfo FS, Abass MK, et al,. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2014; 58: 1161-1166.
11. Chauty A, Ardant MF, Adeye A, et al,. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 2007; 51: 4029-4035.
12. Vouking MZ, Tamo VC, Tadenfok CN,. Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review. Pan Afr Med J 2013; 15: 155.
13. Hasumi J, Fukasawa C, Hoshino T, Hamada H, Ohkusu K,. A case of cervical skin ulcers by Mycobacterium ulcerans subsp. shinshuense. J Pediatr Infect Dis Immunol 2011; 23: 383-388.
14. Onoe H, Yotsu RR, Nakanaga K, Hoshino Y, Ishii N, Takeuchi T,. Buruli ulcer accompanied by pain in a Japanese patient. J Dermatol 2012; 39: 869-870.
15. World Health Organization. Tuberculosis [internet]. 2014. Avialable from: http://www.who.int/mediacentre/factsheets/fs104/en/.
16. World Health Organization. Leprosy [internet]. 2014. Avialable from: http://www.who.int/mediacentre/factsheets/fs101/en/.
17. Chauty A, Ardant MF, Marsollier L, et al,. Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis 2011; 52: 94-96.
18. O'Brien DP, McDonald A, Callan P, et al,. Successful outcomes with oral fluoroquinolones combined with rifampicin in the treatment of Mycobacterium ulcerans: an observational cohort study. PLoS Negl Trop Dis 2012; 6: e1473.
19. Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA,. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995; 39: 1700-1703.
20. Portaels F, Traore H, De Ridder K, Meyers WM,. In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother 1998; 42: 2070-2073.
21. Alffenaar JW, Nienhuis WA, de Velde F, et al,. Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection. Antimicrob Agents Chemother 2010; 54: 3878-3883.
22. Hasegawa N, Nishimura T, Watabnabe M, et al,. Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease. Pulm Pharmacol Ther 2009; 22: 190-193.
23. Chen J, Raymond K,. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob 2006; 5: 3.
24. Benedetti MS,. Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs. Pharmacol Res 1995; 32: 177-187.
25. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K,. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995; 171: 747-750.
26. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, Grosset JH,. Activities of rifampin, Rifapentine and clarithromycin alone and in combination against Mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis 2011; 5: e933.
27. Sarfo FS, Phillips R, Asiedu K, et al,. Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 2010; 54: 3678-3685.
28. Pommelet V, Vincent QB, Ardant MF, et al,. Findings in patients from Benin with osteomyelitis and polymerase chain reaction-confirmed Mycobacterium ulcerans infection. Clin Infect Dis 2014; 59: 1256-1264.